Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical study evaluating BioTTT001 for safety and preliminary efficacy in patients with malignant solid tumors, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BioTTT001

Snippet

Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Conditions: Solid Tumor | Phase 1 | Status: ENROLLING_BY_INVITATION